New Heart Disease Drug in Phase 2 testing.
Citing initial results from a Phase 2 trial for the once-daily drug in patients with cardiovascular risk factors and obesity, the California-based biopharma said VTX3232 was safe and well-tolerated among study subjects.
The 12-week study evaluated VTX3232’s safety and tolerability as its primary goal, and the company measured the drug’s effect on high-sensitivity C-reactive protein (hsCRP) as the trial’s secondary goal related to inflammation.
As for hsCRP levels in the full analysis, there was a 64% reduction in the biomarker from baseline among patients treated with VTX3232 compared to a 3% rise in the placebo group.
“These results support further development and VTX3232’s potential to address the high burden of disease caused by inflammation,” said Ventyx’s (NASDAQ:VTYX) medical chief, Mark Forman.
http://seekingalpha.com/news/4507405-ventyx-up-mid-stage-trial-data-heart-drug
3 Likes
